schizophrenia

3D Rendering futuristic robot technology development artificial intelligence
Biotech

MapLight illuminates $262M IPO plans to fund Cobenfy competitor

MapLight is hoping to raise up to $262 million from its IPO, with the proceeds earmarked for its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy.
James Waldron Oct 7, 2025 6:30am
IPO initial public offering Wall Street

Big Pharma-backed MapLight plots IPO

Sep 22, 2025 1:57pm
Money frozen in ice

CNS biotech attempts to break the IPO ice

Aug 25, 2025 11:10am
colorful brain art model

Atai's schizophrenia drug fails to improve cognition in phase 2

Jul 28, 2025 7:45am
The Top Line

What were the biggest clinical trial flops of 2024?

Feb 21, 2025 9:00am
Graphic showing arrows missing the bullseye on a target

2024's top 10 clinical trial flops

Feb 18, 2025 3:00am